John Stanford, Founder and Executive Director of Incubate, recently advocated on Capitol Hill for the U.S. biotech industry, framing its success as critical to national security, healthcare access, and economic competitiveness. Engaging with leaders from Big Pharma and venture capital, he highlighted the detrimental effects of FDA inconsistencies and proposed price control policies, such as the Most Favored Nation (MFN) initiative, which could hinder innovation and isolate the U.S. market.

Stanford’s discussions underscored the potential risks posed by the Inflation Reduction Act (IRA), which allows Medicare to negotiate drug prices, particularly affecting small-molecule drugs. Research indicates a significant drop in venture capital investments in this sector since the IRA’s enactment. He emphasized the need for stable regulatory guidance from the FDA to maintain its status as a global leader in drug development.

A key takeaway is the importance of legislative efforts like the Ensuring Pathways to Innovative Cures Act, which aims to amend the IRA and extend the negotiation timeline for small-molecule drugs. This could help safeguard the U.S. biotech landscape against growing international competition, particularly from China.

Source: fiercebiotech.com